<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04336852</url>
  </required_header>
  <id_info>
    <org_study_id>2020-0318</org_study_id>
    <secondary_id>1F32HL144082-01A1</secondary_id>
    <secondary_id>5F32HL144082-02</secondary_id>
    <nct_id>NCT04336852</nct_id>
  </id_info>
  <brief_title>Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function</brief_title>
  <official_title>Development of a Clinically-relevant Test for Assessment of Cerebral Vascular Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Illinois at Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to develop a test of cerebral vessel function by inducing a&#xD;
      reactive hyperemia that will elicit a rapid and profound increase in cerebral vessel shear&#xD;
      stress. The results of this project may lead to development of a test with&#xD;
      prognostic/predictive utility for individual risk assessment of a future cerebrovascular&#xD;
      event/disease. This information will be of vital importance to the medical community in&#xD;
      regards to cerebrovascular health in aging individuals, and testing of interventions and&#xD;
      therapies that may ameliorate these effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2018</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Three groups of subjects (young, older, cigarette smokers) complete the same intervention, in an independent-group design.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cerebral vascular function</measure>
    <time_frame>3-months</time_frame>
    <description>Assessment of internal carotid artery dilation and blood flow in response to a reactive hyperemic stimulus</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cerebral vascular reactivity to carbon dioxide (CO2)</measure>
    <time_frame>3-months</time_frame>
    <description>Assessment of blood flow (or velocity) through the internal carotid artery and middle cerebral artery with a standardized CO2 stimulus (+5 mmHg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flow mediated dilation (brachial and femoral arteries)</measure>
    <time_frame>3-months</time_frame>
    <description>Assessment of artery dilation and blood flow in response to a reactive hyperemic stimulus</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">93</enrollment>
  <condition>Cerebrovascular Disorders</condition>
  <condition>Cerebrovascular Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Flow mediated dilation (brachial and femoral arteries)</intervention_name>
    <description>Assessment of vascular function of the brachial and femoral arteries.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cerebral vascular reactivity to carbon dioxide (CO2)</intervention_name>
    <description>Cerebral blood flow responses to increasing partial pressure of CO2</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cerebral vascular function test</intervention_name>
    <description>Cerebral blood flow responses to a reactive hyperemia stimulus</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Young and Older Healthy Adults:&#xD;
&#xD;
          -  Males and females willing and able to provide informed consent&#xD;
&#xD;
          -  Aged between 18-35 years (Young) or 60-80 years (Older)&#xD;
&#xD;
          -  Premenopausal women will be tested within 1-4 days after menses begins to control for&#xD;
             hormone status&#xD;
&#xD;
          -  Women taking oral contraceptives will be allowed to participate and they will be&#xD;
             tested in the low hormone or placebo phase&#xD;
&#xD;
          -  Postmenopausal women (at least 12 months since last menstrual cycle) who are not on&#xD;
             hormone replacement therapy will be eligible&#xD;
&#xD;
          -  Sedentary or recreationally active&#xD;
&#xD;
          -  Non-tobacco/nicotine users (e.g., cigarettes, chewing tobacco, nicotine gum or&#xD;
             patches)&#xD;
&#xD;
          -  Laboratory measured systolic blood pressure &lt;140 mmHg and diastolic blood pressure &lt;90&#xD;
             mmHg&#xD;
&#xD;
          -  Normal 12-lead ECG (reviewed by a physician)&#xD;
&#xD;
          -  Normal clinical results from a medical exam reviewed by a board certified physician&#xD;
             (e.g., Medical &amp; Behavioral Health Questionnaire - see attached document)&#xD;
&#xD;
          -  Body mass index (BMI) &lt;40 kg/m2 unless athletic/muscular build; calculation = body&#xD;
             weight (kg)/height (m2); this criteria is used to ensure subjects will fit inside the&#xD;
             LBNP chamber&#xD;
&#xD;
          -  Females only: documentation of a negative pregnancy test prior to the familiarization&#xD;
             and experimental sessions&#xD;
&#xD;
        Young and Older Chronic Smokers of Tobacco Cigarettes:&#xD;
&#xD;
        The same criteria (a-c and e-i above) as Young and Older Healthy Adults, except:&#xD;
&#xD;
        - Chronic smokers of tobacco cigarettes only (i.e., at least 20 pack year use)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Young and Older Healthy Adults:&#xD;
&#xD;
          -  Age &lt;18 years, or 40-60 years, or &gt;80 years&#xD;
&#xD;
          -  Body mass index (BMI) &gt;40 kg/m2 unless athletic/muscular build; calculation = body&#xD;
             weight (kg)/height (m2)&#xD;
&#xD;
          -  Regular tobacco/nicotine users within the last 6 months (e.g., cigarettes, chewing&#xD;
             tobacco, nicotine gum or patches)&#xD;
&#xD;
          -  Not abstaining from the following 24 hours prior to the familiarization session and&#xD;
             the experimental session: exercise, alcoholic substances, prescription or&#xD;
             non-prescription medications (unless cleared by the medical screener), dietary&#xD;
             supplements, herbal medications, caffeinated substances (including coffee, tea (iced&#xD;
             or hot), caffeinated energy drinks or sodas).&#xD;
&#xD;
          -  Not fasted for at least 3-4 hours prior to the experimental sessions.&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Hormone replacement therapy (males and females)&#xD;
&#xD;
          -  Females with an erratic/irregular menstrual cycle&#xD;
&#xD;
          -  Females who are using a continually-releasing hormonal (e.g., NuvaRingâ„¢ or other&#xD;
             hormone-releasing vaginal rings, Depo Provera shot, birth control implants such as&#xD;
             Nexplanon) and who do not have a regular menstrual cycle&#xD;
&#xD;
          -  Use of prescription drugs, non-prescription drugs or herbal medicines known to alter&#xD;
             autonomic function unless cleared prior to the study&#xD;
&#xD;
          -  Any metabolic disease, except individuals who are on cholesterol-lowering medications&#xD;
             (older subjects only; young subjects on cholesterol-lowering medications will be&#xD;
             excluded)&#xD;
&#xD;
          -  Use of two or more anti-hypertensive medications (older subjects only; young subjects&#xD;
             on anti-hypertensive medications will be excluded)&#xD;
&#xD;
          -  Use of beta blockers&#xD;
&#xD;
          -  Frequent use of bronchodilators&#xD;
&#xD;
          -  Use of anti-coagulant therapy&#xD;
&#xD;
          -  Current or past history of hyperthyroidism, or other thyroid hormone-related disease&#xD;
&#xD;
          -  Signs of cardiovascular abnormalities (e.g., resting systolic blood pressure &gt;140 mmHg&#xD;
             or diastolic blood pressure &gt;90 mmHg; abnormal 12-lead ECG)&#xD;
&#xD;
          -  History of cerebrovascular abnormalities (e.g., prior stroke, transient ischemic&#xD;
             attacks, epilepsy)&#xD;
&#xD;
          -  Known history of atherosclerosis of the carotid arteries (i.e., plaque formation)&#xD;
&#xD;
          -  Known history of peripheral artery disease (PAD)&#xD;
&#xD;
          -  Concussion and or other loss of consciousness within the past 30 days.&#xD;
&#xD;
          -  Autonomic dysfunction (e.g., Shy-Drager Syndrome, Bradbury-Eggleston syndrome, sinus&#xD;
             arrhythmia, idiopathic orthostatic hypotension, fainting disorder)&#xD;
&#xD;
          -  Respiratory illnesses (e.g., chronic asthma (including exercise-induced asthma),&#xD;
             Chronic Obstructive Pulmonary Disease, Reactive Airway Disease)&#xD;
&#xD;
          -  History of anaphylaxis&#xD;
&#xD;
          -  History of pre-syncopal/syncopal episodes or orthostatic hypotension&#xD;
&#xD;
          -  Donated blood within the last 60 days&#xD;
&#xD;
          -  History or family history of abnormal blood clotting, clots in deep veins in the legs&#xD;
             or pelvis, or blood clots to the lungs&#xD;
&#xD;
          -  Known or suspected abdominal hernia&#xD;
&#xD;
          -  History of alcohol or drug abuse which inhibits the subject's ability to complete this&#xD;
             study&#xD;
&#xD;
          -  Known depression, anxiety, or any other mental health issue which inhibits the&#xD;
             subject's ability to complete this study&#xD;
&#xD;
        Young and Older Chronic Smokers of Tobacco Cigarettes&#xD;
&#xD;
        The same criteria (a-b and d-dd above) as Young and Older Healthy Adults, except:&#xD;
&#xD;
        - Less than 20 pack year use of tobacco cigarettes, or regular use of other&#xD;
        tobacco/nicotine products within the last 6 months (e.g., electronic cigarettes, chewing&#xD;
        tobacco, nicotine gum or patches).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexander J Rosenberg, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Illinois at Chicago</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alexander J Rosenberg, PhD</last_name>
    <phone>312-996-9607</phone>
    <email>arosen26@uic.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bo Fernhall, PhD</last_name>
    <phone>312-996-6695</phone>
    <email>fernhall@uic.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexander J Rosenberg, PhD</last_name>
      <phone>312-996-9607</phone>
      <email>arosen26@uic.edu</email>
    </contact>
    <contact_backup>
      <last_name>Bo Fernhall, PhD</last_name>
      <phone>312-996-6695</phone>
      <email>fernhall@uic.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Tracy Baynard, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Texas Health Science Center</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Rickards, PhD</last_name>
      <phone>817-735-2735</phone>
      <email>caroline.rickards@unthsc.edu</email>
    </contact>
    <investigator>
      <last_name>Caroline Rickards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 1, 2020</study_first_submitted>
  <study_first_submitted_qc>April 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 7, 2020</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Illinois at Chicago</investigator_affiliation>
    <investigator_full_name>Alexander (AJ) Rosenberg</investigator_full_name>
    <investigator_title>Principal Investigator, NIH F32 Postdoctoral Fellow</investigator_title>
  </responsible_party>
  <keyword>brain blood flow</keyword>
  <keyword>brain vascular function</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cerebrovascular Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

